The UK private healthcare market is an attractive prospect for many private equity firms, but navigating this landscape requires a deep understanding of key metrics and considerations.
UK private healthcare is now one of the most active investment categories for private equity in the UK. Rare. works with multiple PE firms entering the market through M&A or de novo investment, and the questions they ask in diligence and post-deal value creation cluster into a recurring pattern. We call it the 5 Ps of Private Equity in Healthcare: Place, Product, Patient, People, Performance.
1. Place
Location dictates almost every other variable in private healthcare. Income distribution, demographic composition, and local NHS pressure vary enormously within local authority boundaries, and that variation translates directly into demand. PE diligence on Place focuses on three questions:
Hotspots. Where is demand for private healthcare service concentrated?
Demographics. What are the income, age, and household profile of the catchment area?
Accessibility. How far will patients travel for the treatment? Rare. data finds 51% of aesthetics patients will travel over an hour for treatment, which materially expands the catchment for any clinic offering the right specialism.
2. Product
Product covers the service offering, the pricing, and the way the offering is operationalised. Investors look for:
Proposition. What unique value does the provider deliver, and is that value clinically defensible?
Market gap. What unmet need is being addressed in this catchment, and who else competes for it?
Pricing. Is the pricing competitive and sustainable, and is there headroom for growth?
Product stickiness. What are patient retention rates and repeat-treatment rates?
Occupancy. How efficiently is the physical capacity being used?
Asset optimisation. Are there clear opportunities to improve efficiency and revenue per square metre?
3. Patient
Long-term commercial value sits in the patient relationship, not the individual treatment. Diligence on Patient covers:
Customer lifetime value. The total revenue per patient over the relationship.
Cross-sell and upsell. The ability to extend the relationship into adjacent services.
Patient satisfaction. How the provider compares against named competitors on retention-relevant satisfaction measures.
4. People
Healthcare businesses live and die on the team. Investors test:
Team strength. Is the management team capable and experienced, and how reliant is the business on the founders?
Staff retention. Are clinical and commercial staff committed long-term?
Customer relationships. Are patient relationships built on trust in the institution, or on individual clinicians who could leave?
5. Performance
Financial performance is the answer the rest of the diligence is trying to predict. Standard tests:
EBITDA. Pre-tax earnings as the primary profitability measure.
Balance sheet. Indicators of underlying financial health and resilience.
Profitability. Whether margin levels are healthy and sustainable through cycles.
Retention mechanisms. Whether the business has structural patient retention through membership schemes or equivalent.
Where Rare.Monitor sits
The 5 Ps framework is only as strong as the data behind it. Rare.Monitor provides the supply-side data, financial, operational, treatment-level, and the demand-side data, patient behaviour and intent, that PE teams need to answer each P with evidence rather than inference. Most diligence questions in private healthcare resolve to a data question, and the data has historically been hard to find. That has changed.
What this means for operators
For healthcare providers seeking PE investment, optimising against the 5 Ps significantly improves the diligence process and the valuation. Operators who can present clear evidence on each P, particularly Patient lifetime value and Performance retention mechanisms, command better terms than those who cannot.
